Memantine: Efficacy and safety in mild-to-severe Alzheimer's disease

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 2, 2007, Pages 245-258

  Tampi, Rajesh R ^a   van Dyck, Christopher H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Memantine; NMDA antagonist

Indexed keywords

CHOLINESTERASE INHIBITOR; DIZOCILPINE; DONEPEZIL; GALANTAMINE; KETAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PHENCYCLIDINE; PLACEBO; RIVASTIGMINE;

ACCIDENTAL INJURY; AGITATION; ALZHEIMER DISEASE; ANOREXIA; ANXIETY; ARTICLE; BACKACHE; BRAIN ISCHEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFUSION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEMENTIA; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG WITHDRAWAL; FALLING; FECES INCONTINENCE; FLU LIKE SYNDROME; GAIT; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERTENSION; INSOMNIA; MONOTHERAPY; NAUSEA; NONHUMAN; PERIPHERAL EDEMA; PREDICTION; QUALITY ADJUSTED LIFE YEAR; RECOMMENDED DRUG DOSE; RHINITIS; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URINE INCONTINENCE; VOMITING;

EID: 34249910587     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: 10.2147/nedt.2007.3.2.245     Document Type: Article

References (56)

1. [APA] American Psychiatric Association. 1987. Diagnostic and Statistical Manual of Mental Disorders, 3rd edition. (DSM-III-R). Washington D.C.: American Psychiatric Association.
2. [APA] American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. (DSM-IV). Washington D.C.: American Psychiatric Association.
3. Bakchine S, Pascual-Gangnant L, Loft H. 2005. Results of a randomised, placebo-controlled 6-month study of memantine in the treatment of mild to moderate Alzheimer's disease in Europe. 9th Congress of the European Federation of the Neurological Societies, (EFNS). Athens, Greece.
4. Chen H, Pellegrini J, Aggarwal S, et al. 1992. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity. J Neurosci, 12:4427-36.
5. Cummings J. 2003. Use of cholinesterase inhibitors in clinical practice: evidence-based recommendations. Am J Geriatr Psychiatry, 11:131-45.
6. Cummings J, Mega M, Gray K, et al. 1994. The Neuropsychiatric Inventory; comprehensive assessment of psychopathology in dementia. Neurology, 44:2308-14.
7. Danysz W, Parsons C. 2003. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry, 18:S23-32.
8. Doraiswamy PM. 2002. Non-cholinergic strategies for treating and preventing Alzheimer's disease. CNS Drugs, 16:811-24.
9. Ferm L. 1974. Behavioral activities in demented geriatric patients. Gerontol Clin, 16:185-94.
10. Folstein M, Folstein S, McHugh P. 1975. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12:189-98.
11. Forest Laboratories, Inc. 2003. Namenda®: U.S. package insert, NewYork: Forest Laboratories, Inc.
12. Forest Laboratories, Inc. 2004. FDA accepts supplemental New Drug Application filing to expand Namenda's indication to include treatment for mild Alzheimer's disease (media release).
13. Forest Laboratories, Inc. 2005. Forest Laboratories, Inc. Announces FDA Decision on Supplemental New Drug Application for Namenda® (media release).
14. Fox C, Maidment ID, Boustani M, et al 2006. Memantine combined with an acetylcholinesterase inhibitor - hope for the future. Neuropsychiatric Disease and Treatment, 2:121-5.
15. Galasko D, Schmitt F, Thomas R, et al. 2005. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc, 11:446-53.
16. Gauthier S, Wirth Y, Mobius HJ. 2005. Effects of memantine on behavioral symptoms in Alzheimer's disease patients: and analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psychiatry, 20:459-64.
17. Grossberg G, Desau A. 2003. Management of Alzheimer's disease. J Gerontol A Biol Sci Med Sci, 58:331-53.
18. Hartmann S, Mobius H. 2003. Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy. Int Clin Psychopharmacol, 18:81-5.
19. Hebert L, Scherr P, Bienias J, et al. 2003. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol, 60:1119-22.
20. Heim C, Sontag K. 1995. Memantine prevents progressive functional neurodegeneration in rats. J Neural Transm Suppl, 46:117-30.
21. Johnson N, DavisT, Bosanquet N. 2000. The epidemic of Alzheimer's disease. How can we manage the costs? Pharmacoeconomics, 18:215-34.
22. Jones R, Bayer A, Inglis F, et al. 2005. Once-daily dosing of memantine found to be as safe and tolerable as twice-daily dosing in a 12-week, double-blind study in moderate to severe Alzheimer's disease. 12th International Congress of the Internaitonal Psychogeriatric Association (IPA). Stockholm, Sweden.
23. Jonsson L. 2005. Cost effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden. Am J Geriatric Pharmacother, 3:77-86.
24. Jorm A. 1991. Cross-national comparisons of the occurrence of Alzheimer's and vascular dementias. Eur Arch Psychiatry Clin Neurosci, 240:218-22.
25. Kornhuber J, Quack G. 1995. Cerebrospinal fluid and serum concentrations of the N-methyl-D-aspartate (NMDA) receptor antagonist memantine in man. Neurosci Lett, 195:137-9.
26. Lipton SA. 2004. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurological disorders. J Alzheimer's Dis, 6:S 61-74.
27. Livingston G, Katona C. 2004. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry, 19:919-25.
28. Lundbeck Pharmaceuticals, Inc. 2004. Lundbeck files for the mild to moderate indication for Alzheimer's disease (media release).
29. McKhann G, Drachman D, Folstein M, et al. 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology, 34:939-44.
30. Mobius H, Stoffler A. 2002. New approaches to clinical trials in vascular dementia: memantine in small vessel disease. Cerebrovasc Dis, 13:61-6.
31. Orgogozo J, Rigaud A, Stoffler A, et al. 2002. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke, 33:1834-9.
32. Parsons C, Danysz W, Quack G. 1999. Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist: a review of preclinical data. Neuropharmacology, 38:735-67.
33. Periclou A, Ventura D, Sherman T, et al. 2004. Lack of pharmacokinetic or pharmacodynamic interaction between memantine and donepezil. Ann Pharmacother, 38:1389-94.
34. Peskind ER, Potkin SG, Pomara N, et al. 2006. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry, 14:704-15.
35. Plosker G, Lyseng-Williamson K. 2005. Memantine: a pharmacoeconomic review of its use in moderate to severe Alzheimer's disease. Pharmacoeconomics, 23:193-206.
36. Reisberg B, Doody R, Stoffler A, et al. 2003. Memantine in moderate to severe Alzheimer's disease. N Engl J Med, 348:1333-41.
37. Reisberg B, Ferris S, de Leon M, et al. 1982. The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry, 139:1136-9.
38. Rive B, Vercelletto M, Damier F, et al. 2004. Memantine enhances autonomy in moderate to severe Alzheimer's disease. Int J Geriatr Psychiatry, 19:458-64.
39. Rogawski M, Wenk G. 2003. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev, 9:275-308.
40. Rosen W, Mohs R, Davis K. 1984. A new rating scale for Alzheimer's disease. Am J Psychiatry, 141:1356-64.
41. Rosen W, Terry R, Fuld P, et al. 1980. Pathological verification of ischaemic score in differentiation of dementias. Ann Neurol, 7:486-8.
42. Schmitt F, Ashford W, Ernesto C, et al. 1997. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord, 11:S51-6.
43. Schneider L, Olin J, Doody R, et al. 1997. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord, 11:S22-32.
44. Sclan S, Reisberg B. 1992. Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity and ordinality. Int Psychogeriatr, 4:55-69.
45. Seif el Nasr M, Peruche B, Rossberg C, et al. 1990. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol, 185:19-24.
46. Small G, Rabins P, Barry P, et al. 1997. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society. JAMA, 278:1363-71.
47. Tariot P, Farlow M, Grossberg G, et al. 2004. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA, 291:317-24.
48. van der Kam P, Hoeksma B. 1989. The usefulness of BOP and SIVIS (ADL and behavior rating scales) for the estimation of workload in a psychogeriatric nursing home. Results of a time-standard study. Tijdschr Gerontol Geriatr, 20:159-66.
49. van Dyck CH, Schmitt FA, Olin JT. 2006. A responder analysis of memantine treatment in Alzheimer's disease patients maintained on donepezil. Am J Geriatr Psychiatry, 14:428-37.
50. van Dyck CH, Tariot PN, Meyers B, et al. 2007. A 24-week randomized, controlled trial of memantine in patients with moderate to severe Alzheimer disease. Alzheimer Dis Assoc Disord. In press.
51. Wenk G, Zajaczkowski W, Danysz W. 1997. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B. Behav Brain Res, 83:129-33.
52. Wilcock G, Mobius H, Stoffler A. 2002. A double-blind, placebo controlled multicenter study of memantine in mild to moderate vascular dementia (MMM 500). Int Clin Psychopharmacol, 17:297-305.
53. Wimo A, Winblad B, Aguero-Torres H, et al. 2003. The magnitude of dementia occurrence in the world. Alzheimer Dis Assoc Disord, 17:63-7.
54. Winblad B, Poritis N. 1999. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry, 14:135-46.
55. Yao C, Raoufinia A, Gold M, et al. 2005. Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol, 45:519-28.
56. Zeger SL, Liang KY. 1986. Longitudinal data analysis for discrete and continuous outcomes. Biometrics, 42:121-30.